https://stock.noler.com/us/stock/pharmaceutical-product-development-inc https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/accounts-and-other-receivables-net-current https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/accounts-payable https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/accrued-income-taxes-current https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/accrued-income-taxes-noncurrent https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/accrued-liabilities-current https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/accumulated-depreciation https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/accumulated-oci-available-for-sale-adjustment-net-of-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/accumulated-oci-cumulative-changes-in-net-gain-loss-from-cash-flow-hedges-effect-net-of-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/accumulated-oci-defined-benefit-pension-and-other-postretirement-plans-net-of-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/accumulated-oci-foreign-currency-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/acquisitions https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/activist-13d-13g-form-sc-13g https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/adjustments-noncash-items-to-reconcile-net-income-loss-to-cash-provided-by-used-in-operating-activities-other https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/allowance-for-doubtful-accounts-receivable https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/amended-reports-10-k https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/aoci https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/assets-fair-value-disclosure https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/available-for-sale-debt-current https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/available-for-sale-debt-noncurrent https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/available-for-sale-failed-auction-value https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/available-for-sale-gross-realized-gains https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/available-for-sale-gross-unrealized-gain https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/available-for-sale-gross-unrealized-losses https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/basic-shares https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/billed-contract-receivables https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/buildings-and-improvements-gross https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/buybacks-share-repurchases https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/buybacks-shares-repurchased https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/buybacks-shares-repurchased-value https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/capital-expenditures https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/cash-and-cash-equivalents-fair-value-disclosure https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/cash-and-equivalents https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/cash-flow-breakdown https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/common-dividends-paid https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/common-stock-dividends-per-share-cash-paid https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/common-stock-value https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/comprehensive-income https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/construction-in-progress-gross https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/cost-method-investments-realized-gains https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/cost-of-services https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/costmethod-investments-realized-losses-excluding-other-than-temporary-impairments https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/costs-and-expenses https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/current-assets https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/current-liabilities https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/deferred-rent-credit-noncurrent https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/deferred-revenue https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/deferred-tax-assets-net-current https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/deferred-tax-assets-net-noncurrent https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/deferred-tax-liabilities-noncurrent https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/defined-benefit-plan-amortization-of-gains-losses https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/defined-benefit-plan-estimated-future-employer-contributions-in-current-fiscal-year https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/defined-benefit-plan-expected-return-on-plan-assets https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/defined-benefit-plan-interest-cost https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/defined-benefit-plan-net-periodic-benefit-cost https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/depreciation https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/depreciation-and-amortization https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/derivative-gain-loss-reclassification-from-accumulated-oci-to-income-estimated-net-amount-to-be-transferred https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/diluted-shares https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/direct-operating-costs https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/discontinued-operation-gain-loss-on-disposal-of-discontinued-operation-net-of-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/discontinued-operation-income-loss-from-discontinued-operation-before-income-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/discontinued-operation-tax-effect-of-discontinued-operation https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/dividends-per-share https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/eps https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/eps-basic https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/escrow-deposit https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/financing-cash-flow https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/finite-lived-intangible-assets-amortization-expense https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/finite-lived-intangible-assets-gross https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/foreign-currency-derivative-assets-at-fair-value https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/foreign-currency-derivative-liabilities-at-fair-value https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/furniture-and-fixtures-gross https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/future-amortization-expense-remainder-of-fiscal-year https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/future-amortization-expense-year-five https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/future-amortization-expense-year-four https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/future-amortization-expense-year-three https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/future-amortization-expense-year-two https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/gain-loss-on-cash-flow-hedge-ineffectiveness-net https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/gain-loss-on-investments https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/gain-loss-on-sale-of-investments https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/goodwill https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/goodwill-purchase-accounting-adjustments https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/goodwill-translation-adjustments https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/impairment-of-intangible-assets-finitelived https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/impairment-of-investments https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/income-loss-from https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/income-loss-from-discontinued-operations-net-of-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/income-loss-from-discontinued-operations-net-of-tax-per-basic-and-diluted-share https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/income-loss-from-discontinued-operations-net-of-tax-per-basic-share https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/income-loss-from-discontinued-operations-net-of-tax-per-diluted-share https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/income-loss-from-equity-method-investments https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/income-loss-from-equity-method-investments-net-of-dividends-or-distributions https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/income-loss-from-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/income-loss-from-per-basic-share https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/income-loss-from-per-diluted-share https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/income-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/income-taxes-receivable https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/increase-decrease-in-accounts-payable-and-accrued-liabilities https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/increase-decrease-in-accrued-income-taxes-payable https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/increase-decrease-in-customer-advances https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/increase-decrease-in-operating-capital https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/increase-decrease-in-other-operating-assets https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/increase-decrease-in-restricted-cash https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/incremental-common-shares-attributable-to-share-based-payment-arrangements https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/indefinite-lived-intangible-assets https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/insider-transactions-other https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/insider-transactions-stock-units https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/investing-cash-flow https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/investment-income-interest https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/land https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/letters-of-credit-outstanding-amount https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/liabilities-fair-value-disclosure https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/line-of-credit-facility-maximum-borrowing-capacity https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/line-of-credit-facility-maximum-monthend-outstanding-amount https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/malpractice-insurance-deductible https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/minority-interest https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/net-change-in-cash https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/net-income https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/net-income-loss-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/notes-receivable-gross https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/number-of-foreign-currency-derivatives-held https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/oci-available-for-sale-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/oci-defined-benefit-plans-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/oci-derivatives-qualifying-as-hedges-tax-effect-change https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax-change https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/oci-net-of-tax-change https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/oci-reclassification-adjustment-for-write-down-of-securities-net-of-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/oci-reclassification-adjustment-for-write-down-of-securities-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/oci-reclassification-adjustment-on-derivatives-net-of-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/oci-reclassification-adjustment-on-derivatives-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/oci-unrealized-gain-loss-on-derivatives-arising-net-of-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/oci-unrealized-gain-loss-on-derivatives-arising-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/oci-unrealized-holding-gain-loss-on-securities-arising-net-of-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/oci-unrealized-holding-gain-loss-on-securities-arising-tax https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/operating-cash-flow https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/operating-income https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/other-current-assets https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/other-depreciation-and-amortization https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/other-income https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/other-long-term-investments https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/other-noncash-income-expense https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/other-noncurrent-assets https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/other-noncurrent-liabilities https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/other-noncurrent-liabilities-2 https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/payments-to-acquire-intangible-assets https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/payments-to-acquire-investments https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/payments-to-acquire-other-investments https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/payments-to-fund-longterm-loans-to-related-parties https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/pension-and-other-postretirement-defined-benefit-plans-liabilities-noncurrent https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/prepaid-expense-current https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/pretax-income https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/proceeds-from-collection-of-longterm-loans-to-related-parties https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/proceeds-from-divestiture-of-businesses https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/proceeds-from-issuance-of-shares-under-incentive-and-share-based-compensation-plans-including-stock-options https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/proceeds-from-sale-maturity-and-collections-of-investments https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/proceeds-from-sale-of-other-investments https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/proceeds-from-sale-of-property-plant-and-equipment https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/property-plant-equipment https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/provision-for-doubtful-accounts https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/public-float https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/redeemable-noncontrolling-interest-equity-common-carrying-amount https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/reimbursement-revenue https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/research-and-development https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/restructuring-charges https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/retained-earnings https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/revenue https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sales-revenue-services-net https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-comment-letters-corresp https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-comment-letters-upload https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-filings-10-k https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-filings-10-k405 https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-filings-10-q https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-filings-15-12g https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-filings-25-nse https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-filings-8-k https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-filings-ars https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-filings-ct-order https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-filings-def-14a https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-filings-defa14a https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-filings-defm14a https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-filings-pre-14a https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-filings-prem14a https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sec-filings-s-4 https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/secondary-offerings-form-s-3 https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/secondary-offerings-form-s-8 https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/secondary-offerings-form-s-8-pos https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/sga-expense https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/shareholders-equity https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/shares-authorized https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/shares-issued https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/shares-issued-2 https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/stock-based-compensation https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/stock-repurchase-program-authorized-amount https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/stock-repurchase-program-remaining-authorized-repurchase-amount https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/stockholders-equity-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/tax-benefit-from-stock-options-exercised https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/temporary-equity-redemption-value https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/total-assets https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/total-liabilities https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/unbilled-contracts-receivable https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/utb-decrease-from-settlements https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/utb-income-tax-penalties-accrued https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/utb-interest-on-income-taxes-accrued https://stock.noler.com/us/stock/pharmaceutical-product-development-inc/utb-that-would-impact-effective-tax-rate